Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: Lancet Infect Dis. 2014 Feb 20;14(5):388–396. doi: 10.1016/S1473-3099(14)70020-9

Table 3.

New HIV-1 infections detected among participants enrolled in the follow-up study with available HIV test resultsa

Total Vaccine Placebo
All 28/421 (6.7%) 15/205 (7.3%) 13/216 (6.0%)
Women 17/190 (8.9%) 7/90 (7.8%) 10/100 (10.0%)
Men 11/231 (4.8%) 8/115 (7.0%) 3/116 (2.6%)
a

Among the 422 participants enrolled in the follow-up study, one woman who received vaccine is pending HIV testing results.

HHS Vulnerability Disclosure